Risk factors and mechanisms for skin squamous cell carcinoma in lung transplant recipients induced by voriconazole

doi:10.19803/j.1672-8629.20220441

Abstract

Abstract: Voriconazole is an effective broad-spectrum antifungal agent characterized by high tolerance, safety and effectiveness that is often used as the first choice for the prevention and treatment of invasive aspergillosis after lung transplantation. With wider clinical application, case reports of voriconazole-related cutaneous squamous cell carcinoma, which is often aggressive and multifocal in nature, are ticking up, making this drug an independent risk factor for squamous cell carcinoma in lung transplant recipients. This article reviews the risk factors and potential mechanisms for the development of squamous cell carcinoma induced by voriconazole in order to provide reference for rational clinical application.

Key words: voriconazole, lung transplant, cutaneous squamous cell carcinoma, risk factors, mechanism

CLC Number:

R978
R994.11

LYU Peng, ZHANG Jingli, WANG Yunhong, MA Fenfen, ZHANG Yu, HUANG Yifei. Risk factors and mechanisms for skin squamous cell carcinoma in lung transplant recipients induced by voriconazole[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 595-600.

References

[1] TSUNG I, WORDEN FP, FONTANA RJ.A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma[J]. Oncologist, 2021, 26(2): 133-138.
[2] CHANG MS, AZIN M, DEMEHRI S.Cutaneous squamous cell carcinoma: the frontier of cancer immunoprevention[J]. Annu Rev Pathol, 2022, 17: 101-119.
[3] NGUYEN CV, HE Q, RADY PL, et al.Presence of human papillomavirus DNA in voriconazole-associated cutaneous squamous cell carcinoma[J]. Int J Dermatol, 2020, 59(5): 595-598.
[4] HUSAIN S, CAMARGO JF.Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice[J]. Clin Transplant, 2019, 33(9): e13544.
[5] MINARI A, HUSNI R, AVERY RK, et al.The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants[J]. Transpl Infect Dis, 2002, 4(4): 195-200.
[6] REN JX, NI SD, LI M, et al.Research progress on influencing factors of voriconazole therapeutic drug concentration monitoring[J]. Drugs & Clinic(现代药物与临床), 2021, 36(7): 1545-1548.
[7] DENNING DW, GRIFFITHS CE.Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole[J]. Clin Exp Dermatol, 2001, 26(8): 648-653.
[8] KOLAITIS NA, DUFFY E, ZHANG A, et al.Voriconazole increases the risk for cutaneous squamous cell carcinoma after lung transplantation[J]. Transpl Int, 2017, 30(1): 41-48.
[9] Pfizer, Inc. VFEND (voriconazole)[EB/OL]. (2022-10-26)[2023-02-21]. https://www.pfizermedicalinformation.cn/products/package-insert/vfend-injection.
[10] HUSAIN S, CAMARGO JF.Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice[J]. Clin Transplant, 2019, 33(9): e13544.
[11] MCCARTHY KL, PLAYFORD EG, LOOKE DF, et al.Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy[J]. Clin Infect Dis, 2007, 44(5): e55-e56.
[12] BRUNEL AS, FRAISSE T, LECHICHE C, et al.Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy[J]. AIDS, 2008, 22(7): 905-906.
[13] ANACKER A, FABRÉ G, VAN DORPE J, et al.Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient[J]. Am J Transplant, 2008, 8(4): 877-880.
[14] COWEN EW, NGUYEN JC, MILLER DD, et al.Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole[J]. J Am Acad Dermatol, 2010, 62(1): 31-37.
[15] EPAULARD O, SAINT-RAYMOND C, VILLIER C, et al.Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients[J]. Clin Microbiol Infect, 2010, 16(9): 1362-1364.
[16] IBRAHIM SF, SINGER JP, ARRON ST.Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole[J].Dermatol Surg, 2010, 36(11): 1752-1755.
[17] MORICE C, ACHER A, SOUFIR N, et al.Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report[J]. Case Rep Med, 2010(4): 351084.
[18] WONG JY, KUZEL P, MULLEN J, et al.Cutaneous squamous cell carcinoma in two pediatric lung transplant patients on prolonged voriconazole treatment[J]. Pediatr Transplant, 2014, 18(6): e200-e207.
[19] ZHANG S, NEUJAHR DC, ZWALD FO.Recurrent and metastatic squamous cell carcinoma in lung transplant recipient on voriconazole: lessons learned[J]. JAAD Case Reports, 2015, 1(6): S12-S15.
[20] LI AW, LALOR LE, BELLODI SF, et al.A pediatric case of squamous cell cancer in situ in the setting of sclerodermatous graft-versus-host disease and voriconazole treatment[J]. Pediatr Dermatol, 2018, 35(3): e165-e169.
[21] DUSENDANG JR, CARLSON E, LEE DS, et al.Cohort and nested case-control study of cutaneous squamous cell carcinoma in solid organ transplant recipients by medication[J]. J Am Acad Dermatol, 2022, 86(3): 598-606.
[22] VAJDIC CM, VAN LEEUWEN MT.Cancer incidence and risk factors after solid organ transplantation[J]. Int J Cancer, 2009, 125(8): 1747-1754.
[23] GARRETT GL, BLANC PD, BOSCARDIN J, et al.Incidence of and risk factors for skin cancer in organ transplant recipients in the United States[J]. JAMA Dermatol, 2017, 153(3): 296-303.
[24] NOBEYAMA Y, UMEZAWA Y, ASAHINA A.Risk of squamous cell carcinoma in immunosuppressed patients with voriconazole-related actinic keratosis[J]. J Dermatol, 2022, 49(11): 1168-1172.
[25] VADNERKAR A, NGUYEN MH, MITSANI D, et al.Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients[J]. J Heart Lung Transplant, 2010, 29(11): 1240-1244.
[26] FEIST A, LEE R, OSBORNE S, et al.Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole[J]. J Heart Lung Transplant, 2012, 31(11): 1177-1181.
[27] SINGER JP, BOKER A, METCHNIKOFF C, et al.High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients[J]. J Heart Lung Transplant, 2012, 31(7): 694-699.
[28] ZWALD FO, SPRATT M, LEMOS BD, et al.Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation[J]. Dermatol Surg, 2012, 38(8): 1369-1374.
[29] MCLAUGHLIN JM, EQUILS O, SOMERVILLE KT, et al.Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients[J]. Transpl Infect Dis, 2013, 15(4): 329-343.
[30] ELNAHAS S, OLSON MT, KANG P, et al.Factors associated with skin cancer in lung transplant recipients: a single-center experience[J]. Clin Transplant, 2019, 33(12): e13718.
[31] HAMANDI B, FEGBEUTEL C, SILVEIRA FP, et al.Voriconazole and squamous cell carcinoma after lung transplantation: a multicenter study[J]. Am J Transplant, 2018, 18(1): 113-124.
[32] MANSH M, BINSTOCK M, WILLIAMS K, et al.Voriconazole exposure and risk of cutaneous squamous cell carcinoma, Aspergillus colonization, invasive Aspergillosis and death in lung transplant recipients[J]. Am J Transplant, 2016, 16(1): 262-270.
[33] XIANG LP, GONG WJ, WU SL, et al.Research advances of liver injury inducedby triazole antifungal agents[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(14): 1475-1480.
[34] SWANSON HI.Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective[J]. Chem Biol Interact, 2004, 149(2-3): 69-79.
[35] ONA K, OH DH.Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A[J]. Br J Dermatol, 2015, 173(3): 751-759.
[36] BERGE M, GUILLEMAIN R, TRÉGOUET DA, et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients[J]. Eur J Clin Pharmacol, 2011, 67(3): 253-260.
[37] LEE V, GOBER MD, BASHIR H, et al.Voriconazole enhances UV-induced DNA damage by inhibiting catalase and promoting oxidative stress[J]. Exp Dermatol, 2020, 29(1): 29-38.
[38] LIU MM, ZHU YJ, WANG X, et al.A meta-analysis on the relationship between COX-2 and skin cancer development[J]. Journal of Harbin Medical University(哈尔滨医科大学学报), 2016, 50(1): 85-89.
[39] IKEYA S, SAKABE JI, YAMADA T, et al.Voriconazole-induced photocarcinogenesis is promoted by aryl hydrocarbon receptor-dependent COX-2 upregulation[J]. Sci Rep, 2018, 8(1): 5050.